EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib

Andrea Casadei‐Gardini, Giuseppe Cabibbo, Vincenzo Dadduzio, Giulia Orsi, Ranka Vukotic, Mario Domenico Rizzato, Margherita Rossi, Valeria Guarneri, Sara Lonardi, Dario D'Agostino, Ciro Celsa, Giulia Rovesti und 7 weitere

Liver Cancer International · 2020

DOI: 10.1002/lci2.12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver Cancer International, 2020. Verfasst von Andrea Casadei‐Gardini und 18 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recently developed PROSASH model is proving to be a useful tool in risk‐group discrimination in hepatocellular carcinoma (HCC) patients treated with sorafenib. Several studies highlighted that the neutrophil‐to‐lymphocyte ratio (NLR) is one of the most important predictors of survival in HCC patients treated with sorafenib. The aims of the present study were to validate the PROSASH model and determine whether the incorporation of inflammatory markers can improve risk stratification. This study included 438 patients. According to the four categories of the PROSASH model, median overall survival (OS) was 20.0, 14.9, 8.5 and 3.0 months respectively ( P < .001). The Harrell's c for this categorized model was 0.621. NLR (cut‐off 3) stratified OS in each of the PROSASH categories. After reclassification, median OS was 21.0, 15.1, 8.2 and 4.1 months ( P < .001). The Harrell's c increased from 0.621 to 0.673 ( P = .001). Integrating NLR into the PROSASH model allowed a more accurate classification of the patients in the risk groups.

Zitieren

APA

Casadei‐Gardini, A., Cabibbo, G., Dadduzio, V., Orsi, G., Vukotic, R., Rizzato, M. D., Rossi, M., Guarneri, V., Lonardi, S., D'Agostino, D., Celsa, C., Rovesti, G., Rimini, M., Andreone, P., Zagonel, V., Scartozzi, M., Johnson, P., Cascinu, S., & Cucchetti, A. (2020). Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib. Liver Cancer International. https://doi.org/10.1002/lci2.12

Vancouver

Casadei‐Gardini A, Cabibbo G, Dadduzio V, Orsi G, Vukotic R, Rizzato MD, et al. Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib. Liver Cancer International. 2020. doi:10.1002/lci2.12

BibTeX
@article{CasadeiGardini2020,
  author = {Casadei‐Gardini, Andrea and Cabibbo, Giuseppe and Dadduzio, Vincenzo and Orsi, Giulia and Vukotic, Ranka and Rizzato, Mario Domenico and Rossi, Margherita and Guarneri, Valeria and Lonardi, Sara and D'Agostino, Dario and Celsa, Ciro and Rovesti, Giulia and Rimini, Margherita and Andreone, Pietro and Zagonel, Vittorina and Scartozzi, Mario and Johnson, Philip and Cascinu, Stefano and Cucchetti, Alessandro},
  title = {Validation and refinement of PROSASH model using the neutrophil‐to‐lymphocyte ratio in patients with HCC receiving sorafenib},
  journal = {Liver Cancer International},
  year = {2020},
  doi = {10.1002/lci2.12}
}
Kostenlos starten →